Toth Financial Advisory Corp Has $721,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Toth Financial Advisory Corp grew its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 1,450.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,550 shares of the pharmaceutical company's stock after buying an additional 1,450 shares during the period. Toth Financial Advisory Corp's holdings in Vertex Pharmaceuticals were worth $721,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Groesbeck Investment Management Corp NJ boosted its stake in Vertex Pharmaceuticals by 1.2% during the 2nd quarter. Groesbeck Investment Management Corp NJ now owns 1,794 shares of the pharmaceutical company's stock worth $841,000 after purchasing an additional 21 shares during the period. Institute for Wealth Management LLC. boosted its stake in Vertex Pharmaceuticals by 0.6% during the 2nd quarter. Institute for Wealth Management LLC. now owns 3,586 shares of the pharmaceutical company's stock worth $1,681,000 after purchasing an additional 22 shares during the period. Drive Wealth Management LLC boosted its stake in Vertex Pharmaceuticals by 2.0% during the 2nd quarter. Drive Wealth Management LLC now owns 1,101 shares of the pharmaceutical company's stock worth $516,000 after purchasing an additional 22 shares during the period. Daymark Wealth Partners LLC boosted its stake in Vertex Pharmaceuticals by 2.8% during the 3rd quarter. Daymark Wealth Partners LLC now owns 804 shares of the pharmaceutical company's stock worth $374,000 after purchasing an additional 22 shares during the period. Finally, Grove Bank & Trust boosted its stake in Vertex Pharmaceuticals by 5.7% during the 3rd quarter. Grove Bank & Trust now owns 410 shares of the pharmaceutical company's stock worth $191,000 after purchasing an additional 22 shares during the period. Institutional investors and hedge funds own 90.96% of the company's stock.

Insider Buying and Selling

In related news, Director Bruce I. Sachs sold 5,295 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $508.00, for a total value of $2,689,860.00. Following the completion of the sale, the director now owns 40,000 shares in the company, valued at approximately $20,320,000. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 5,295 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $508.00, for a total value of $2,689,860.00. Following the completion of the transaction, the director now owns 40,000 shares of the company's stock, valued at $20,320,000. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Sangeeta N. Bhatia sold 646 shares of the business's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $500.00, for a total transaction of $323,000.00. Following the transaction, the director now directly owns 4,435 shares of the company's stock, valued at approximately $2,217,500. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,285 shares of company stock worth $7,101,755. Insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Price Performance

VRTX opened at $478.09 on Tuesday. The company's 50 day simple moving average is $475.48 and its 200 day simple moving average is $460.75. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.26 and a current ratio of 2.52. Vertex Pharmaceuticals Incorporated has a 1 year low of $341.90 and a 1 year high of $510.64. The stock has a market capitalization of $123.40 billion, a PE ratio of -235.51 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The business had revenue of $2.65 billion during the quarter, compared to analysts' expectations of $2.66 billion. Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The company's quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.53 EPS. As a group, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post -2.11 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on VRTX shares. Wells Fargo & Company increased their price target on shares of Vertex Pharmaceuticals from $540.00 to $555.00 and gave the stock an "overweight" rating in a research note on Monday, June 24th. Royal Bank of Canada cut their price objective on shares of Vertex Pharmaceuticals from $431.00 to $425.00 and set a "sector perform" rating for the company in a research report on Friday, October 4th. JPMorgan Chase & Co. upped their price objective on shares of Vertex Pharmaceuticals from $505.00 to $510.00 and gave the stock an "overweight" rating in a research report on Monday, August 5th. StockNews.com downgraded shares of Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, August 5th. Finally, Oppenheimer upped their price objective on shares of Vertex Pharmaceuticals from $500.00 to $550.00 and gave the stock an "outperform" rating in a research report on Monday, August 5th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $492.92.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.